Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 3:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 241 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Aged Healthy Volunteer Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.

NCT07283263
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-985521, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Vitamin B3 Derivative Nicotinamide Riboside (NR) in Bone, Skeletal Muscle and Metabolic Functions in Aging

NCT03818802
View directory record Official record
Conditions
Healthy Elderly Volunteers
Interventions
Nicotinamide Riboside, Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years to 80 Years · Female only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Jul 23, 2026, 3:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Normal Donor Sample Collection Study in Healthy Adults

NCT01318863
View directory record Official record
Conditions
Healthy Normal Volunteers
Interventions
Not listed
Lead sponsor
Astute Medical, Inc.
Industry
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
6
States / cities
Santa Ana, California • Las Vegas, Nevada • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2011 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults

NCT01678287
View directory record Official record
Conditions
Healthy Volunteers, Pharmacokinetics of ASP1941
Interventions
ASP1941, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2012 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers

NCT02691702
View directory record Official record
Conditions
Healthy Adult Subjects, Healthy Elderly Subjects
Interventions
BIIB118, Melatonin
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 85 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers

NCT00214461
View directory record Official record
Conditions
Clostridium Infections
Interventions
Vaccine diluent buffer (Placebo), C. difficile toxoid vaccine (2 µg), C. difficile toxoid vaccine (10 µg), C. difficile toxoid vaccine (50 µg)
Biological
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
2
States / cities
Orlando, Florida • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 10, 2012 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults

NCT03039790
View directory record Official record
Conditions
Healthy Volunteers, Norovirus
Interventions
NoV Vaccine
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
9
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Littleton, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Neuromodulation of Cognition in Older Adults

NCT02137122
View directory record Official record
Conditions
Healthy
Interventions
Sham Stimulation, Transcranial Direct Current Stimulation
Device
Lead sponsor
University of Florida
Other
Eligibility
65 Years to 90 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2023 · Synced Jul 23, 2026, 3:38 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years

NCT06573281
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Investigational RSV vaccine 1, Investigational RSV vaccine 2, Investigational RSV vaccine 3, Investigational RSV vaccine 4, Investigational RSV vaccine 5, Investigational RSV vaccine 6, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
5
States / cities
Rolling Hills Estates, California • Atlanta, Georgia • Lenexa, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects

NCT01739647
View directory record Official record
Conditions
Healthy Young Volunteers, Healthy Elderly Volunteers
Interventions
AZD3293, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2013 · Synced Jul 23, 2026, 3:38 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older

NCT01132859
View directory record Official record
Conditions
Immunity, Mucosal, Immune System Processes, Blood Specimen Collection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Male and Female Participants 18 to ≤55 Years of Age

NCT06665555
View directory record Official record
Conditions
Pharmacokinetics, Healthy Volunteers
Interventions
ledaborbactam etzadroxil, ceftibuten
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Dosing Study of IkT-148009.

NCT06641557
View directory record Official record
Conditions
Healthy
Interventions
200mg of Ikt-148009
Drug
Lead sponsor
ABLi Therapeutics, Inc.
Industry
Eligibility
45 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers

NCT04074837
View directory record Official record
Conditions
Alzheimer Disease
Interventions
NNI-362, Placebo
Drug
Lead sponsor
Neuronascent, Inc.
Industry
Eligibility
50 Years to 72 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Heat Wrap Device Safety With Age and Body Fat

NCT01355653
View directory record Official record
Conditions
Back Pain
Interventions
thermal therapy, ThermaCare heatwrap
Device
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 84 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Jul 23, 2026, 3:38 PM EDT
Completed No phase listed Observational

Influence of Age and Sex on Alcohol Metabolism and Acute Responses

NCT00070577
View directory record Official record
Conditions
Metabolism
Interventions
Not listed
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Celebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population

NCT00137033
View directory record Official record
Conditions
Peptic Ulcers
Interventions
Celecoxib, Naproxen, ASA
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
605 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
23
States / cities
Anaheim, California • San Diego, California • Farmington, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-Label, Placebo-Controlled, Parallel Group Study in Healthy Volunteers to Evaluate the Effects of Two Single MT 400 or Naproxen Sodium Tablets

NCT00596245
View directory record Official record
Conditions
Healthy
Interventions
MT400
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 35 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation of Adhesion and Dermal Tolerability of EMSAM

NCT00531596
View directory record Official record
Conditions
Healthy
Interventions
EMSAM (Selegiline Transdermal System) 6mg/24Hr, EMSAM (Selegiline Transdermal System) 9mg/24Hr, EMSAM (Selegiline Transdermal System) 12mg/24hr
Drug
Lead sponsor
Somerset Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Scottsdale, Arizona • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2007 · Synced Jul 23, 2026, 3:38 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Visual Arts Interventions With Older Adults

NCT06645652
View directory record Official record
Conditions
Feasibility Study
Interventions
Training in observational drawing, Arts engagement through digital galleries
Behavioral
Lead sponsor
Northeastern University
Other
Eligibility
55 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 23, 2026, 3:38 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

NCT04762511
View directory record Official record
Conditions
Herpes Simplex
Interventions
Lower dose formulation of HSV vaccine (GSK4108771A), Low dose formulation of HSV vaccine (GSK4108771A), Medium dose formulation of HSV vaccine (GSK4108771A), High dose formulation of HSV vaccine (GSK4108771A), Placebo (saline)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Lenexa, Kansas • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K

NCT01364974
View directory record Official record
Conditions
Healthy Subjects, Pharmacokinetics of ASP015K, Pharmacodynamics
Interventions
ASP015K, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2011 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

NCT05050318
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants

NCT04713553
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
BNT162b2, BNT162b2.B.1.351
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
12 Years to 50 Years
Enrollment
1,574 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
17
States / cities
Oakland, California • Milford, Connecticut • Hialeah, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Jul 23, 2026, 3:38 PM EDT